Scholarlink

Background <p>Dapagliflozin has been shown in preclinical and clinical settings to improve arterial function and left ventricular (LV) diastolic performance, yet the interrelationship between these effects has not been established.</p> Objective <p>To determine whether improvements in endothelial function accompany—and relate to—early changes in LV diastolic function after short-term dapagliflozin in type 2 diabetes (T2D).</p> Methods <p>We conducted a prespecified secondary analysis of a prospective, open-label, active-controlled trial of patients with T2D on background metformin that were randomized to daily dapagliflozin 10&#xa0;mg or glibenclamide 5&#xa0;mg for 12 weeks. All patients underwent echocardiographic and endothelial function assessments at baseline and 12 weeks. The primary endpoint for echocardiographic diastolic parameters was the change in E/e′. Endpoints for endothelial function were change in brachial artery flow-mediated dilation (FMD) and nitric oxide (NO) bioavailability. Arterial load comprises arterial impedance, measured as the brachial artery resistivity index, and the afterload components, the systemic vascular resistance and the ventriculo-arterial coupling index, as a marker of arterial stiffness.</p> Results <p>Among 96 patients (mean age 59 years; 40% female; baseline HbA1c 7.8%; 75% at intermediate risk H2FPEF score), glycemic control improved similarly in both groups (median [IQR] HbA1c change: −0.78 [0.11]% vs. −0.80 [0.10]%; between-group <i>p</i> = 0.887). Dapagliflozin reduced the E/e’ ratio (mean change − 0.38 [0.24]; within-group <i>p</i> = 0.184), whereas glibenclamide increased (+ 0.79 [0.24]; <i>p</i> = 0.001), resulting in a significant between-group difference of − 1.17 (0.34; <i>p</i> = 0.001). Dapagliflozin treatment was associated with a 67% lower likelihood of being in a higher E/e’ quartile (OR 0.325; 95% CI 0.147–0.715; <i>p</i> = 0.005). In the pooled cohort, changes in E/e’ correlated directly with changes in brachial resistive index (<i>r</i> = 0.28; <i>p</i> = 0.005) and inversely with changes in NO bioavailability (<i>r</i> = − 0.26; <i>p</i> = 0.010) and FMD (<i>r</i> = − 0.23; <i>p</i> = 0.023). No significant correlations were observed for systemic vascular resistance or ventricle-arterial coupling.</p> Conclusions <p>In patients with T2D at intermediate risk for HFpEF, dapagliflozin was associated with more favorable changes in left ventricular diastolic function parameters compared with glibenclamide, accompanied by improvements in endothelial function and reductions in arterial impedance. These observations support the hypothesis of a vascular–myocardial pathway through which SGLT2 inhibition may exert cardioprotective effects in this population.</p> Trial registration <p>ClinicalTrials.gov Identifier NCT 02919345.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Sheila T. Kimura-Medorima,
  • Daniela C Oliveira,
  • Ikaro Breder,
  • Vaneza Lira W. Wolf,
  • Alexandre A.S. Soares,
  • Joaquim Barreto,
  • Daniel B. Munhoz,
  • Jessica S. Cunha,
  • Isabella Bonilha,
  • Luiz Sergio F. de Carvalho,
  • Otavio R. Coelho-Filho,
  • José Roberto Matos-Souza,
  • Filipe A. Moura,
  • Wilson Nadruz,
  • Thiago Quinaglia,
  • Andrei C. Sposito

摘要

Background

Dapagliflozin has been shown in preclinical and clinical settings to improve arterial function and left ventricular (LV) diastolic performance, yet the interrelationship between these effects has not been established.

Objective

To determine whether improvements in endothelial function accompany—and relate to—early changes in LV diastolic function after short-term dapagliflozin in type 2 diabetes (T2D).

Methods

We conducted a prespecified secondary analysis of a prospective, open-label, active-controlled trial of patients with T2D on background metformin that were randomized to daily dapagliflozin 10 mg or glibenclamide 5 mg for 12 weeks. All patients underwent echocardiographic and endothelial function assessments at baseline and 12 weeks. The primary endpoint for echocardiographic diastolic parameters was the change in E/e′. Endpoints for endothelial function were change in brachial artery flow-mediated dilation (FMD) and nitric oxide (NO) bioavailability. Arterial load comprises arterial impedance, measured as the brachial artery resistivity index, and the afterload components, the systemic vascular resistance and the ventriculo-arterial coupling index, as a marker of arterial stiffness.

Results

Among 96 patients (mean age 59 years; 40% female; baseline HbA1c 7.8%; 75% at intermediate risk H2FPEF score), glycemic control improved similarly in both groups (median [IQR] HbA1c change: −0.78 [0.11]% vs. −0.80 [0.10]%; between-group p = 0.887). Dapagliflozin reduced the E/e’ ratio (mean change − 0.38 [0.24]; within-group p = 0.184), whereas glibenclamide increased (+ 0.79 [0.24]; p = 0.001), resulting in a significant between-group difference of − 1.17 (0.34; p = 0.001). Dapagliflozin treatment was associated with a 67% lower likelihood of being in a higher E/e’ quartile (OR 0.325; 95% CI 0.147–0.715; p = 0.005). In the pooled cohort, changes in E/e’ correlated directly with changes in brachial resistive index (r = 0.28; p = 0.005) and inversely with changes in NO bioavailability (r = − 0.26; p = 0.010) and FMD (r = − 0.23; p = 0.023). No significant correlations were observed for systemic vascular resistance or ventricle-arterial coupling.

Conclusions

In patients with T2D at intermediate risk for HFpEF, dapagliflozin was associated with more favorable changes in left ventricular diastolic function parameters compared with glibenclamide, accompanied by improvements in endothelial function and reductions in arterial impedance. These observations support the hypothesis of a vascular–myocardial pathway through which SGLT2 inhibition may exert cardioprotective effects in this population.

Trial registration

ClinicalTrials.gov Identifier NCT 02919345.

Graphical abstract